Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03
Journal of Clinical Oncology, 09/28/09
Roh MS et al. – Preoperative chemoradiotherapy, compared with postoperative chemoradiotherapy, significantly improved DFS and shows a trend toward improved OS.
Methods- Patients with clinical T3 or T4 or node-positive rectal cancer randomly assigned to preoperative or postoperative chemoradiotherapy
- Chemotherapy consisted of fluorouracil and leucovorin with 45 Gy in 25 fractions with 5.40-Gy boost within original margins of treatment
- In preop group, surgery was performed within 8 weeks after completion of radiotherapy
- In postop group, chemotherapy began after recovery from surgery but no later than 4 weeks postop
- Primary end points were DFS and OS
- From August 1993 to June 1999, 267 patients randomly assigned to NSABP R-03
- Intended sample size 900 patients
- Excluding 11 ineligible and two eligible patients without follow-up data, analysis used data on 123 patients randomly assigned to preop and 131 to postop chemoradiotherapy
- Surviving patients observed for median of 8.4 years
- 5-year DFS for preop was 64.7% v 53.4% for postop
- Complete pathologic response achieved in 15% of preop patients
- No preop patient with complete pathologic response has had recurrence
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell–fibronectin adhesion of colon cancer cells
Oncogene, 11/25/09
A blood-based biomarker panel for stratifying current risk for colorectal cancer
International Journal of Cancer, 11/25/09
iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells
Molecular Cancer, 11/24/09
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma
Journal of Cancer Research & Clinical Oncology, 11/24/09
Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-mTOR pathway
Journal of Clinical Oncology, 11/24/09
Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro
Molecular Cancer, 11/23/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


